Latest News

Friday, December 19, 2014 |

Study Supports Benefit of Widely Used Glaucoma Drug

Prostaglandin analogue eye drops -- a common form of glaucoma drug -- significantly reduce the risk of vision loss in patients with the eye disease, a new study finds. British researchers led by David…

Read the full story

Friday, December 19, 2014 | Clinical Trials

LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery

LayerBio is an MIT spin-off developing novel drug delivery products for ophthalmology and wound care. The National Eye Institute at the National Institutes of Health has awarded LayerBio a phase 1 SBI…

Read the full story

Friday, December 19, 2014 | Product Releases

Second Sight’s Argus II Retinal Prosthetic Implant to be Sold in Turkey

Second Sight Medical Products announced that it has entered into an exclusive agreement with distributor Erişçi Elektronik Ltd. (“Erisci Elektronik”) to offer the world’s fir…

Read the full story

Friday, December 19, 2014 |

Autologous Serum Eye Drops Safe, Effective for Dry Eyes

Autologous serum (AS) 50% eye drops appear to be safe and effective for dry eye disease in the long term, especially in patients with severe disease refractory to conventional treatment, according to …

Read the full story

Thursday, December 18, 2014 | Management/Leadership, SCHWIND eye-tech-solutions

New Head of Sales at Schwind Eye-Tech-Solutions

Starting January 1, 2015, Michael Fichtner, 52, will become the new head of sales at Schwind eye-tech-solutions, according to a company news release. He brings with him more than 25 years of int…

Read the full story

Thursday, December 18, 2014 | Clinical Trials

Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis

Aldeyra Therapeutics announced that an investigational new drug application (IND) to conduct phase 2 clinical testing of NS2 for the treatment of noninfectious anterior uveitis was submitted to the FD…

Read the full story

Thursday, December 18, 2014 | Acquisitions/Mergers

Shire Said to Weigh Offer for NPS as It Revisits Deals

Shire, looking to boost growth after its proposed sale to Abbvie Inc. collapsed, is considering a bid for NPS Pharmaceuticals, people familiar with the matter said. Shire is interested in Bedminster, …

Read the full story

Thursday, December 18, 2014 | Medical Studies

Groundbreaking Wireless Material May Restore Sight to Blind Retinas

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration. New progress …

Read the full story

Wednesday, December 17, 2014 | Glaucoma

Prevent Blindness Study Projects Number of Cases and Costs Related to Glaucoma to Soar

According to the 2014 Prevent Blindness “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems” report, more than 2.8 million Americans currently have glaucoma. Those n…

Read the full story

Wednesday, December 17, 2014 | Management/Leadership

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition

Actavis announced the planned senior management team that will lead the company following the close of the acquisition of Allergan, anticipated in the second quarter of 2015, according to a company ne…

Read the full story

Wednesday, December 17, 2014 | Medical Studies

The Human Eye Can See 'Invisible' Infrared Light

Any science textbook will tell you we can't see infrared light. Like X-rays and radio waves, infrared light waves are outside the visual spectrum. But an international team of researchers co-led b…

Read the full story

Tuesday, December 16, 2014 | Earnings & Financials

Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index

Aerie Pharmaceuticals announced that it has been selected for addition to the NASDAQ Biotechnology Index, which will become effective upon market open on Monday, December 22, 2014. The NASDAQ Biote…

Read the full story

Tuesday, December 16, 2014 | Medical Studies

Artificial Retina Steps Closer With Groundbreaking Wireless Material

A proof-of-concept study published in the journal Nano Letters, reports how a groundbreaking new material can activate brain neurons in response to light without the use of wires to an external source…

Read the full story

Tuesday, December 16, 2014 | Health Care

Vivek Murthy, MD, Confirmed as Surgeon General

The Senate today confirmed Vivek Murthy, MD, as the nation's next Surgeon General as Democrats took advantage of their soon-to-end majority status to overcome GOP opposition to President Barack Ob…

Read the full story

Monday, December 15, 2014 | Retina, Genentech

FDA Grants Breakthrough Therapy Designation for Lucentis for the Treatment of Diabetic Retinopathy

The FDA has granted breakthrough therapy designation for Lucentis (ranibizumab; Genentech) for the treatment of diabetic retinopathy, according to a company statement. A medicine may be designated …

Read the full story
Load More

Advertisement

 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $30.25  0.51% 
 Akorn, Inc. $38.19  -0.58% 
 Alimera Sciences, Inc. $5.69  -0.70% 
 Allergan, Inc. $213.92  0.82% 
 Avalanche $50.50  0.28% 
 Bayer $139.43  -1.73% 
 Can-Fite Biopharma $3.39  -2.24% 
 Carl Zeiss Meditec $20.55  1.08% 
 Cooper Companies, Inc. $162.62  0.21% 
 Escalon Medical Corp. $1.45  -4.61% 
 Essilor International $110.25  0.00% 
 Imprimis Pharmaceuticals, Inc. $8.45  -0.47% 
 InSite Vision, Inc. $0.21  -0.92% 
 IRIDEX Corporation $8.87  0.68% 
 Johnson & Johnson $105.91  -0.84% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $53.94  0.26% 
 Merck & Company, Inc. $59.80  1.39% 
 NicOx $1.99  -0.70% 
 NovaBay Pharmaceuticals, Inc. $0.67  6.03% 
 Novartis AG Common Stock $94.86  0.30% 
 Ocular Therapeutix $21.25  3.76% 
 Ophthotech Corporation $47.11  -0.76% 
 Quantel $3.24  -2.99% 
 Regeneron $430.80  1.65% 
 Roche $34.44  -6.67% 
 STAAR Surgical Company $9.27  0.54% 
 TearLab Corporation $2.54  3.64% 
 Thrombogenics $7.80  0.00% 
 Topcon Corporation $21.66  0.00% 
 Valeant Pharmaceuticals $146.25  2.27% 
 Xoma $4.20  -1.18%